Details
Category: Volume 07 Issue 09 September 2019
Hits: 1380

Title: Schizophrenia and depression are mental disorders with wide range of psychiatric manifestations

Authors: Ankita Kumari Soni, Dr Sumit Kumar Tiwari, Dr Bushra Fiza, Dr Maheep Sinha

 DOI: https://dx.doi.org/10.18535/jmscr/v7i9.67

Abstract

    

Objectives: The present study was performed to the assess the levels of thyroid profile and mineral profile in patients of schizophrenia & depression.

Material & Methods: 50 patients diagnosed for schizophrenia & 50 with depression visited the Out-patient Department (OPD) of Department of Psychiatric at Mahatma Gandhi Medical College & Hospital, Jaipur were enrolled for the study based on the predefined inclusion and exclusion criteria.

Observations: TSH levels (P=0.019) were significantly higher in the schizophrenia group whereas T3 (P=0.004) &T4 (P=0.001) values were significantly lower, serum Ca levels were lower (P= 0.000). serum Po4 levels were significantly higher. (P=0.000) decrease serum Mg levels in schizophrenia group as compared to control group (P=0.003).

TSH levels were high in patient’s depression. (P=0.076) and less Serum T3 (P=0.000) and T4 (P=0.000) was observed in depression group. serum Ca and Mg levels were significantly lower in depression group (P=0.000) (P=0.020) respectively. the serum Po4 levels were significantly higher. (P=0.004)

Conclusion: we concluded that in psychiatric disorder, thyroid hormones levels tend to be lower. This suggested hypo activity of thyroid gland. The study also reported decreased level of Ca & Mg and increased serum Po4 levels. Derangement of the above minerals can lead to several complications. Thyroid hormones are responsible for regulation of the basal metabolic rate. Patients with psychiatric manifestations should be recommended screening for thyroid & mineral profile

Keywords: Schizophrenia, depression, hormonal , profile and mineral profile.

References

  1. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Canadian J Psychiatry. 2002;47(9):833-843.
  2. National Institute of Mental Health. Depression. NIH Publications, 2008.
  3. Spratt D, Pont A, Miller MB, McDougall IR, Bayer MF, Mclaughlin WT: Hyperthyroxinemia in patient with acute psychiatric disorder. Am j med 1982; 73:41-47
  4. Kelly DL, Conley RR. Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. J Clin Psychiatry. 2005;66(1):80-4.
  5. Sim K, Chong SA, Chan YH, Lum WM. Thyroid dysfunction in chronic schizophrenia within a state psychiatric hospital. Ann Acad Med Singapore.2002; 31:641-664.
  6. Santos NC, Costa P, Ruano D, Macedo A, Soares MJ, Valente J, et al. Revisiting thyroid hormones in schizophrenia. J Thyroid Res. 2012; 2012:569147.
  7. Poyraz BC, Aksoy C, Balcioglu I. Increased incidence of autoimmune thyroiditis in patients with antipsychotic-induced hyperprolactinemia. Eur Neuropsychopharmacol. 2008; 18:667-672.
  8. 8Lin YT, Liao SC. Hashimoto encephalopathy presenting as schizophrenia-like disorder. Cogn Behav Neurol.2009; 22:197-201.
  9. Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry.2006; 163:521-528.
  10. Chaube R, Joy KP. Thyroid hormone modulation of brain in vivo tyrosine hydroxylase activity and kinetics in the female catfish Heteropneustes fossilis. J Endocrinol.2003;179(2):205-215.
  11. Rao ML, Gross G, Huber G. Altered interrelationship of dopamine, prolactin, thyrotropin and thyroid hormone in schizophrenic patients. Eur Arch Psychiatry NeuroSci.1984;234(1):8–12.
  12. 12Wijsman LW, de Craen AJ, Trompet S, Gussekloo J, Stott DJ, Rodondi N et al. Subclinical thyroid dysfunction and cognitive decline in old age. PloS one. 2013;8(3): e59199.
  13. Trzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J. A psychiatric and neuropsychological study of patients with untreated Graves’ disease. Gen Hosp Psychiatry. 1988; 10:49–55.
  14. 14Wolkowitz OM, Rothschild AJ. Psychoneuroendocrinology: The Scientific Basis of Clinical Practice, American Psychiatric, Washington, DC, USA, 1st 2003.
  15. Feldman AZ, Shrestha RT, Hennessey JV. Neuropsychiatric manifestations of thyroid disease. Endocrinol MetabClin North Am. 2013; 42:453-476.
  16. Minerals. National Library of Medicine, US National Institutes of Health. 22 December 2016.
  17. Kandel ER. Transmitter release. In: Kandel ER, Schwartz JH, Josell TM (eds). Principles of Neural Science, Third Edition. Norwalk: Appleton & Lange, 1991:194–212.
  18. Raina R, Garg G, Sethi SK, Schreiber MJ, Simon JF, Thomas G. Phosphorus metabolism. J Nephrol Ther. 2012; 3:2161-0959.
  19. Liukkonen T, Silvennoinen-Kassinen S, Jokelainen J, Rasanen P, Leinonen M, Meyer-Rochow VB et al. The association between C-reactive protein levels and depression: Results from the northern Finland 1966 birth cohort study. Biol Psychiatry, 2006, 60, 825–830.
  20. Malpuech-Brugere C, Nowacki W, Daveau M, Gueux E, Linard C, Rock E, Lebreton J et al. Inflammatory response following acute magnesium deficiency in therat. Biochim Biophys Acta. 2000;1501: 91-98.
  21. Akiibinu MO, Ogundahunsi OA, Ogunyemi EO. Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics. BMC Res Notes. 2012;5(1):169.
  22. Yazici K et. al.,2002 Yazici K, Yazici AE, Taneli B. Different neuroendocrine profiles of remitted and nonremitted schizophrenic patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2002;26(3):579-584.
  23. Baumgartner A, Pietzcker A, Gaebel W. The hypothalamic–pituitary–thyroid axis in patients with schizophrenia. Schizophrenia Res. 2000 Sep 1;44(3):233-243.
  24. Ripova D, Strunecka A, Nemcova V, Farska I. Phospholipids and calcium alterations in platelets of schizophrenic patients. Physiol Res. 1997;46(1):59-68.
  25. Das I, Khan NS, Puri BK, Sooranna SR, Debelleroche J, Hirsch SR. Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophy Res Comm. 1995;212(2):375-380.
  26. Chen X, Li Y, Zhang T, Yao Y, Shen C, Xue Y. Association of Serum Trace Elements with Schizophrenia and Effects of Antipsychotic Treatment. Biol Tr Elem Res. 2018;181(1):22-30.
  27. Deicken RF, Calabrese G, Merrin EL, Fein G, Weiner MW. Basal ganglia phosphorous metabolism in chronic schizophrenia. Am J Psychiatry. 1995;152(1):126.
  28. Nechifor M et. al., 2004. Nechifor M, Vaideanu C, Palamaru I, Borza C, Mindreci I. The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia. J Am Col Nutr. 2004;23(5):549S-551S.
  29. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Association, 2013.
  30. Bauer M, Goetz T, Glenn T, Whybrow PC. The Thyroid‐Brain Interaction in Thyroid Disorders and Mood Disorders. J Neuroendocrinol. 2008;20(10):1101-1114.
  31. Chueire VB, Romaldini JH, Ward LS. Subclinical hypothyroidism increases the risk for depression in the elderly. Arch Gerontol Geriatrics. 2007;44(1):21-28.
  32. Joffe RT, Marriott M. Thyroid hormone levels and recurrence of major depression. Am J Psychiatry. 2000;157(10):1689-1691.
  33. Cole DP, Thase ME, Mallinger AG, Soares JC, Luther JF, Kupfer DJ, et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry. 2002;159(1): 116-121.
  34. Sandstead HH, Frederickson CJ, Penland JG. History of zinc as related to brain function. J Nutr. 2000;130(2):496S-502S.
  35. Levine J, Stein D, Rapoport A, Kurtzman L. High serum and cerebrospinal fluid Ca/Mg ratio in recently hospitalized acutely depressed patients. Neuro-psycho biol. 1999;39(2):63-70.
  36. Young T, Robb JC, Levitt AJ, Cooke RG, Joffe RT. Serum Mg2+ and Ca2+/Mg2+ ratio in major depressive disorder. Neuro-psycho biol. 1996;34(1):26-28.
  37. Shealy CN. Neurochemical Substrates of Depression and their Relation to Cardiac Disease. Clinically Relevant Risk Factor Management of Cardiac Disease Springfield MO. 1991: 15–16.
  38. Cernak I, Savic V, Kotur J, Prokic V, Kuljic B, Grbovic D, etal. Alterations in magnesium and oxidative status during chronic emotional stress. Magnes Res.2000; 12:29-36.

Corresponding Author

Dr Sumit Kumar Tiwari

Senior Demonstrator, Department of Biochemistry, Mahatma Gandhi University of Medical Sciences & Technology, Jaipur Rajasthan